Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
  • Clinical Data

Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout

BioSpace

While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.

Clinical DataCardiovascularRead full story

pharminent March 30, 2026 (Last updated: March 30, 2026)

BioSpace

While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.

Clinical DataCardiovascularRead full story

Post navigation

Previous: Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug
Next: Blackstone closes $6.3B fund for life sciences investing

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.